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Abstract: Extravasation can present serious accidental complication of intravenous drug application.
While monoclonal antibodies do not show the necrotic potential of cytotoxic chemotherapy drugs,
considerable inflammatory toxicity can occur, necessitating standardized operating procedures for
the management of their extravasation. Here, we report the clinical course and management of
dinutuximab beta extravasation in a 3-year-old child. Dinutuximab beta is a chimeric monoclonal
antibody targeting the GD2 disialoganglioside on the surface of neuroblastoma cells that has in recent
years gained significant importance in the treatment of high-risk neuroblastoma, now contributing
to both first- and second-line therapy protocols. The dinutuximab beta extravasation reported here
occurred when the patient received the antibody cycle as a continuous infusion over a 10-day period
after haploidentical stem cell transplantation for relapsed high-risk neuroblastoma. The extravasated
dinutuximab beta caused local pain, swelling, and hyperemia accompanied by fever and an overall
deterioration in the general condition. Laboratory diagnostics demonstrated an increase in C-reactive
protein level and total white blood cell count. Clinical complication management consisted of
intravenous fluid therapy, local dabbing with dimethyl sulfoxide (DMSO), analgesia with dipyrone,
as well as application of intravenous antibiotics to prevent bacterial superinfection in the severely
immunocompromised host. The patient considerably improved after six days with this treatment
regimen and fully recovered by day 20.
Keywords: cancer; immunotherapy; monoclonal antibody; soft tissue; inflammation
1. Introduction
Dinutuximab beta is a chimeric human/mouse monoclonal IgG1 antibody produced in
the CHO (Chinese hamster ovary) mammalian cell line using recombinant DNA technology.
It recognizes the GD2 disialoganglioside, which has limited expression in normal tissues
but is highly expressed across several tumor entities including neuroblastoma [1]. Among
normal tissues, it is found highly expressed in the central and peripheral nervous system
including peripheral pain fibers [1].
Dinutuximab beta binding to GD2 mediates neuroblastoma cell killing through com-
plement activation and effector cell-mediated cytotoxicity by the activation of Fc receptors
on granulocytes and mononuclear cells [1,2]. Based on its chemical structure, it is rea-
soned that dinutuximab beta is eliminated after proteolytic decomposition [2]. Adverse
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effects of dinutuximab beta include pain, hypersensitivity reactions, and capillary leak
syndrome [1,2].
Neuroblastoma is the most common extracranial solid tumor of infancy and childhood
and is characterized by a diverse biological and clinical behavior. In total, high-risk neurob-
lastoma accounts for approximately 15% of all cancer-related deaths in this age group [3].
First-line therapy consists of induction chemotherapy, surgery, high-dose myeloablative
chemotherapy followed by autologous stem cell reinfusion, radiation of the primary tu-
mor site and remaining active metastatic lesions, as well as five cycles of the chimeric
monoclonal antibody dinutuximab beta in the consolidation phase [4,5]. Further, the combi-
nation of dinutuximab beta with irinotecan and temozolomide showed notable antitumor
activity in patients with refractory or relapsed high-risk neuroblastoma [6,7]. A phase I/II
trial investigating the feasibility of dinutuximab beta immunotherapy after HLA (human
leukocyte antigen) mismatched haploidentical stem cell transplantation demonstrated no
increased risk of inducing graft-versus-host disease and suggested an antitumoral effect of
the new donor-derived immune system [8].
Extravasation can present a serious complication of intravenous antineoplastic therapy.
In this regard, drugs are characterized by their necrotizing effect upon extravasation.
While monoclonal antibodies do not show the necrotic potential of cytotoxic drugs such
as anthracyclines or vinca alkaloids, inflammatory toxicity ranging from very low (i.e.,
bevacizumab and trastuzumab [9–11]) to strong (i.e., ipilimumab [12]) can occur. While
to the best of our knowledge no substance-specific protocol exists for the handling of a
dinutuximab-beta extravasation, generally recommended approaches for the management
of drug extravasations frequently entail ceasing infusion, aspiration and removal of the
cannula under aspiration, immobilization and elevation of the affected limb, application of
dry warmth or cold, dabbing with 99% dimethyl sulfoxide (DMSO), and/or infiltration
with hyaluronidase [10,11].
2. Case Presentation
The 3-year-old Caucasian boy with hemophilia type B was diagnosed with MYCN-
amplified stage M neuroblastoma at the age of 12 months and received multimodal anti-
neoplastic therapy in line with German NB 2017 guidelines [13]. After achieving a first
complete remission prior to high-dose chemotherapy followed by autologous stem cell
rescue, the patient developed an isolated intracerebral/meningeal relapse after four cycles
of dinutuximab beta therapy. Now, at the age of 2 years and 4 months, he was treated
with three cycles of combined chemo-/immunotherapy according to Mody et al. [6,7]
in combination with nine doses of intrathecal topotecan and reached a second complete
remission. Following radiation of all initial macroscopically detectable lesions with 20 Gy,
the patient received an allogeneic haploidentical CD19/TcRAb-depleted stem cell trans-
plantation following a conditioning regimen composed of fludarabin, thiotepa, melphalan,
and anti-T-lymphocyte globulin (ATG) via a double-lumen Hickman catheter. This catheter
had to be replaced by a single-lumen Hickman catheter due to a catheter infection. The
vascular situation did not allow the implantation of another double-lumen catheter. No
other transplant-related complications occurred. At day 60 after haploidentical stem
cell transplantation, craniospinal axis proton therapy was performed with 21.6 cobalt
Gray equivalent (CGE). One month later, the first dinutuximab beta cycle was initiated
in inpatient care in line with the respective protocol recommendation at 10 mg/m2 body
weight/day as a continuous infusion over 10 days [8]. The concentration of the dinutux-
imab beta infusion was 0.11 mg/mL. The patient was severely immunocompromised at
that time with no detectable CD3+, CD4+, and CD8+ cells but sufficient reconstitution of
natural killer cells. The neutrophile count was 1300 per µL blood on day 1 of the cycle.
The supportive treatment regimen consisted of valganciclovir, voriconazole, cotrimoxazole,
ursodeoxycholic acid, and levothyroxine. Factor IX was substituted daily. On day 10 of
the cycle, dislocation of the peripheral vein catheter placed in the left cubital vein alerted
to dinutuximab beta extravasation (Figure 1a). The volume extravasated could not be
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determined with absolute certainty. The extravasated dinutuximab beta caused hyperemia
and localized soft tissue swelling with a central induration of 2 × 2 cm (Figure 1a) as well
as strong pain and fever (Figure 2). Laboratory diagnostics documented a white blood
cell increase to a maximum of 8510 neutrophils per µl blood followed by an increase in
C-reactive protein levels in the blood (Figure 2). Following immediate stop of the din-
utuximab beta infusion and removal of the peripheral vein catheter under continuous
aspiration, an intravenous fluid substitution at 2000 mL/m2/day was started to accelerate
drug decomposition and elimination from the affected soft tissue. Local dabbing of the
hyperemic inflamed soft tissue was carried out with 99% DMSO every four hours. Local
application of dry heat was administered to denature the dinutuximab beta molecule and
thereby to accelerate its decomposition. Elevated positioning of the arm was attempted
but hardly tolerated by the toddler. Local infiltration with hyaluronidase was discussed
but not applied due to the underlying condition of severe hemophilia type B. The patient
required regular dipyrone treatment for sufficient analgesia and received a short-term
intravenous treatment with antibiotics to prevent bacterial superinfection on the basis of
a severely immunosuppressed host (Figure 2). The patient considerably improved after
6 days with this treatment regimen (Figure 1b). Soft tissue sonography performed at day 6
showed a residual liquid encapsulation accompanied by signs of panniculitis (Figure 1c).
























 Figure 1. Photographic documentation of dinutuximab beta extravasation in the soft tissue of the left upper arm in a
3-year-old patient on the day of diagnosis (a) and on day 6 (b): a palpable lesion on day 6 (black arrow) was further
investigated by sonography, which demonstrated an anechoic non-vascularized liquid encapsulation of 2 mL volume
surrounded by panniculitis (c).



































Figure 2. Schematic diagram illustrating the clinical symptoms, laboratory findings, and medical interventions for dinutux-
imab beta extravasation. DMSO, dimethyl sulfoxide; CRP, C-reactive protein; WBC, white blood count.
3. Discussion and Conclusions
In contrast to the absent or weak inflammatory reaction caused by extravasation of
some monoclonal antibodies [9], e report here that dinutuximab beta causes a stro g
local and systemic inflammatory response when extravasated. The symptoms may be
explained by the induction of mechanical allodynia mediated by complement activation
after reactivity of dinutuximab beta with the GD2 antigen localized to the surface of
peripheral nerve fibers and/or myelin in the soft tissue affected [14,15]. Both complement
activation and effector cell-mediated cytotoxicity may have acutely occurred against GD2
expressed on those normal tissues as components of the soft tissue region affected. The
established guidelines for handling extravasations in oncological patients were sufficient
to avoid potentially irreversible tissue damage, to prevent secondary complications such
as superinfections, and to reduce the clinical symptoms caused. Although all symptoms
and signs were fully resolved, the prolonged recovery period of 20 days indicates that
dinutuximab beta application with its generally low infusion rate must be closely monitored
by experienced personnel and should, whenever possible, be conducted via a central line.
Next-generation anti-GD2 antibodies with less cross-reactivity against nontumor tissue
could help prevent complications such as the one reported here in the future. Candidates
include complement-silenced anti-GD2 antibody variants as well as antibodies that target
more tumor-specific GD2 derivatives [15,16].
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